tiprankstipranks
Advertisement
Advertisement
AN2 Therapeutics Holds 2026 Annual Stockholder Meeting
PremiumCompany AnnouncementsAN2 Therapeutics Holds 2026 Annual Stockholder Meeting
2M ago
AN2 Therapeutics Advances Chagas Candidate After Positive Trials
Premium
Company Announcements
AN2 Therapeutics Advances Chagas Candidate After Positive Trials
2M ago
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
Premium
The Fly
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
2M ago
AN2 Therapeutics Launches New $80 Million ATM Program
PremiumCompany AnnouncementsAN2 Therapeutics Launches New $80 Million ATM Program
4M ago
AN2 Therapeutics files $300M mixed securities shelf
Premium
The Fly
AN2 Therapeutics files $300M mixed securities shelf
4M ago
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
Premium
The Fly
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
5M ago
AN2 Therapeutics adjusts leadership roles and executive compensation
PremiumCompany AnnouncementsAN2 Therapeutics adjusts leadership roles and executive compensation
7M ago
AN2 Therapeutics announces FDA clearance of OSHU IND application
Premium
The Fly
AN2 Therapeutics announces FDA clearance of OSHU IND application
7M ago
AN2 Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
AN2 Therapeutics Reports Q3 2025 Financial Results
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100